老虎證券

BRIEF-Innovent Biologics Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Reuters
2025/10/22
BRIEF-<a href="https://laohu8.com/S/IVBIY">Innovent Biologics</a> Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Oct 22 (Reuters) - Innovent Biologics Inc 1801.HK:

  • INNOVENT AND TAKEDA WILL CO-DEVELOP IBI363 PD-1/IL-2Α-BIAS) GLOBALLY AND CO-COMMERCIALIZE IT IN U.S.

  • WILL RECEIVE $1.2 BILLION UPFRONT PAYMENT, INCLUDING STRATEGIC EQUITY INVESTMENT OF $100 MILLION BY WAY OF SUBSCRIPTION

  • CO ALSO ELIGIBLE FOR POTENTIAL MILESTONES TOTALING UP TO $10.2 BILLION

Further company coverage: 1801.HK

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10